506 results on '"Kugathasan, S."'
Search Results
52. O07 PREDICTORS OF CLINICAL OUTCOME IN CHILDREN WITH ULCERATIVE COLITIS (UC)
53. Brief Report: Development of the Inflammatory Bowel Disease Family Responsibility Questionnaire
54. P192 - Disease duration does not affect outcome following infliximab therapy in children with Crohn's disease
55. African and European genetic admixture in African American IBD patients
56. Growth impairment in pediatric Inflammatory Bowel Disease
57. Disease Duration Does Not Affect Outcome Following Infliximab in Children with Crohnʼs Disease
58. P044 RETROSPECTIVE EVALUATION OF THE SAFETY AND EFFECT OF ADALIMUMAB THERAPY (RESEAT) IN PEDIATRIC CROHN'S DISEASE
59. The effects of Infliximab therapy on health-related quality of life in pediatric crohnʼs disease
60. Linear growth during infliximab therapy: Results of the REACH multicenter study
61. Linear Growth During Infliximab Therapy: Results of the REACH Multicenter Study
62. Improvement in a Biomarker of Bone Formation during Infliximab Therapy in Pediatric Crohn's Disease: Results of the REACH Study
63. The Effects of Infliximab Therapy on Health-Related Quality of Life in Pediatric Crohn's Disease
64. CARD15 & IBD5 DO NOT CONTRIBUTE TO CROHN??S DISEASE (CD) SUSCEPTIBILITY IN AFRICAN-AMERICAN & HISPANIC CHILDREN; A MULTI-CENTER STUDY
65. RESOURCE UTILIZATION FOR CHILDREN WITH NEWLY DIAGNOSED INFLAMMATORY BOWEL DISEASE
66. CARD15 gene mutations and risk for early surgery in pediatric-onset Crohn’s disease
67. AN OPEN-LABEL SAFETY, TOLERABILITY, AND EFFICACY STUDY OF NATALIZUMAB IN ADOLESCENTS WITH MODERATELY TO SEVERELY ACTIVE CROHNʼS DISEASE
68. BODY MASS INDEX (BMI) OF IBD CHILDREN AT DIAGNOSIS; THE EFFECTS OF OBESITY EPIDEMIC
69. P0687 CHARACTERIZATION OF HEIGHT AND WEIGHT PATTERNS IN NEWLY DIAGNOSED CHILDREN WITH INFLAMMATORY BOWEL DISEASE (IBD)
70. P0666 LAB PARAMETERS IN CHILDREN WITH INFLAMMATORY BOWEL DISEASE (IBD) AT DIAGNOSIS
71. P0615 STEROID THERAPY IN THE AGE OF INFLIXIMAB (IFX): IMMEDIATE AND 1 YEAR OUTCOME IN NEWLY DIAGNOSED CHILDREN WITH CROHN DISEASE (CD)
72. O0106 THE INCIDENCE AND PREVALENCE OF PEDIATRIC INFLAMMATORY BOWEL DISEASE (IBD) IN THE USA
73. P0712 RE‐EVALUATION OF THE PEDIATRIC CROHN’S DISEASE ACTIVITY INDEX: USEFULNESS IN THE PRACTICE SETTING
74. O0107 A PHASE II, MULTICENTER, OPEN‐LABEL STUDY OF THE SAFETY, TOLERABILITY, AND EFFECTIVENESS OF NATALIZUMAB IN ADOLESCENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE.
75. P0683 WEIGHT STATUS IN PEDIATRIC IBD PATIENTS AT THE TIME OF DIAGNOSIS: EFFECTS OF THE OBESITY EPIDEMIC
76. P0135 PP LEU 1007FSINSC IS STRONGLY ASSOCIATED WITH EARLY ONSET AND STRICTURING CROHN’S DISEASE IN CHILDREN
77. Infliximab binds human monocytes but not mucosal T cells in vitro: No direct anti-T cell mechanism of action
78. A protein-truncating R179X variant in RNF186 confers protection against ulcerative colitis
79. PERCUTANEOUS ENDOSCOPIC CECOSTOMY FOR THE MANAGEMENT OF CHRONIC CONSTIPATION
80. DIFFUSE DIVERTICULOSIS OF COLON WITH SPONTANEOUS PERFORATION IN A CHILD
81. DISTINCT MUCOSAL T-CELL RESPONSES TO IL-12 IN EARLY AND LATE STAGES OF INFLAMMATORY BOWEL DISEASE (IBD)
82. IL-12 receptor β2 chain upregulation in mucosal tcells in early but not late Crohn's disease (CD): implications for variable IFN-γ production during disease progression
83. Resistance of Crohn's disease (CD) mucosal T-cells to cell death is independent of trigger: Decreased anti-Fas and nitric oxide (NO)-induced apoptosis
84. Response to Section Editorsʼ Commentary
85. MUCOSAL T-CELL REACTIVITY IN CHILDREN WITH INTESTINAL INFLAMMATION PREDICTS DIAGNOSIS OF CROHN'S DISEASE (CD) AND ULCERATIVE COLITIS (UC)
86. Stool microbiome communities predict remission in pediatric Crohn’s Disease patients even after start of treatment.
87. 85 DIFFERENTIAL GROWTH AND CLONALITY OF GUT T-CELLS AMONG CROHN'S DISEASE (CD), ULCERATIVE COLITIS (UC), UNDETERMINED INFLAMMATION (NON-IBD) AND CONTROL CHILDREN
88. LONG TERM CIPROFLOXICIN (CIPRO) MAY IMPROVE OUTCOME IN CHILDREN WITH SEVERE IDIOPATHIC COLITIS
89. Comparison of magnetic resonance enterography with endoscopy, histopathology, and laboratory evaluation in pediatric Crohn disease.
90. Association of Crohn's disease, thiopurines, and primary epstein-barr virus infection with hemophagocytic lymphohistiocytosis.
91. Extraintestinal manifestations of pediatric inflammatory bowel disease and their relation to disease type and severity.
92. Infliximab therapy in children with concurrent perianal Crohn disease: observations from REACH.
93. Growth abnormalities persist in newly diagnosed children with crohn disease despite current treatment paradigms.
94. Body mass index in children with newly diagnosed inflammatory bowel disease: observations from two multicenter North American inception cohorts.
95. Letters to the Editor
96. Prolonged duration of response to infliximab in early pediatric Crohn's disease.
97. Pediatric inflammatory bowel disease: clinical and therapeutic aspects.
98. Letters to the Editor
99. Improvement in a biomarker of bone formation during infliximab therapy in pediatric Crohn disease: Results of the REACH study
100. Intrinsic hyperreactivity of mucosal T cells to interleukin-2 in pediatric Crohn's disease
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.